Jason P. Rhodes
CIK: 0001577014
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (96 total)
- Aug 14, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect322.5K shares at avg. $25.00$8.1M - Aug 14, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect1.4M shares at avg. $25.00$34.0M - Aug 14, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect478.4K shares at avg. $25.00$12.0M - Aug 13, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect94.4K shares at avg. $26.20$2.5M - Aug 13, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect268.4K shares at avg. $26.20$7.0M - Aug 13, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect63.6K shares at avg. $26.20$1.7M - Jul 7, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect14.8K shares at avg. $23.62$351K - Jul 7, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect5K shares at avg. $23.61$118K - Jul 7, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect11.7K shares at avg. $23.62$276K - Jul 7, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect49.2K shares at avg. $23.17$1.1M - Jul 7, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect62.5K shares at avg. $23.17$1.4M - Jul 7, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect29.6K shares at avg. $23.62$699K - Jul 7, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect124.4K shares at avg. $23.17$2.9M - Jul 6, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect253K shares at avg. $22.79$5.8M - Jul 6, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect100K shares at avg. $22.79$2.3M - Jul 6, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect127.2K shares at avg. $22.79$2.9M - Jun 29, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect40.7K shares at avg. $21.14$860K - Jun 29, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect51.8K shares at avg. $21.14$1.1M - Jun 29, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect103K shares at avg. $21.14$2.2M - Jun 26, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect81.9K shares at avg. $21.28$1.7M - Jun 26, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect64.4K shares at avg. $21.28$1.4M - Jun 26, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect163K shares at avg. $21.28$3.5M - Jun 25, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect12.7K shares at avg. $21.10$268K - Jun 25, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect5K shares at avg. $21.10$106K - Jun 25, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect6.4K shares at avg. $21.10$135K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 14, 2026 |  DYN Dyne Therapeutics, Inc. | Sale(S) | 322,465 | $25.00 | $8,061,625 | Indirect |
| Aug 14, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 1,359,674 | $25.00 | $33,991,850 | Indirect |
| Aug 14, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 478,377 | $25.00 | $11,959,425 | Indirect |
| Aug 13, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 94,415 | $26.20 | $2,473,673 | Indirect |
| Aug 13, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 268,354 | $26.20 | $7,030,875 | Indirect |
| Aug 13, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 63,643 | $26.20 | $1,667,447 | Indirect |
| Jul 7, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 14,844 | $23.62 | $350,615 | Indirect |
| Jul 7, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 5,000 | $23.61 | $118,050 | Indirect |
| Jul 7, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 11,665 | $23.62 | $275,527 | Indirect |
| Jul 7, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 49,193 | $23.17 | $1,139,802 | Indirect |
| Jul 7, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 62,543 | $23.17 | $1,449,121 | Indirect |
| Jul 7, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 29,587 | $23.62 | $698,845 | Indirect |
| Jul 7, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 124,379 | $23.17 | $2,881,861 | Indirect |
| Jul 6, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 253,039 | $22.79 | $5,766,759 | Indirect |
| Jul 6, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 100,019 | $22.79 | $2,279,433 | Indirect |
| Jul 6, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 127,182 | $22.79 | $2,898,478 | Indirect |
| Jun 29, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 40,702 | $21.14 | $860,440 | Indirect |
| Jun 29, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 51,756 | $21.14 | $1,094,122 | Indirect |
| Jun 29, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 102,969 | $21.14 | $2,176,765 | Indirect |
| Jun 26, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 81,903 | $21.28 | $1,742,896 | Indirect |
| Jun 26, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 64,411 | $21.28 | $1,370,666 | Indirect |
| Jun 26, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 162,954 | $21.28 | $3,467,661 | Indirect |
| Jun 25, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 12,699 | $21.10 | $267,949 | Indirect |
| Jun 25, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 5,019 | $21.10 | $105,901 | Indirect |
| Jun 25, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 6,382 | $21.10 | $134,660 | Indirect |
1-25 of 96 transactions
About Rhodes Jason P
Rhodes Jason P (SEC CIK 0001577014) files insider reports with the SEC as Director of Dyne Therapeutics, Inc. (DYN) and Director of Generation Bio Co. (GBIO).
Signal8 holds 14 ownership filings by Rhodes Jason P, all Form 4s, filed between Nov 18, 2024 and Aug 17, 2026. Those filings report 96 transactions, from Nov 14, 2024 to Aug 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Rhodes Jason P's filings is in WALTHAM, MA.
Recent filings by Rhodes Jason P
- Aug 14, 2026: Open-market sales of DYN shares (3 lines, Form 4, code S).
- Aug 13, 2026: Open-market sales of DYN shares (3 lines, Form 4, code S).
- Jul 7, 2026: Open-market sales of DYN shares (7 lines, Form 4, code S).
- Jul 6, 2026: Open-market sales of DYN shares (3 lines, Form 4, code S).
- Jun 29, 2026: Open-market sales of DYN shares (3 lines, Form 4, code S).
Other insiders filing for Dyne Therapeutics, Inc. (DYN)
- Kerr Douglas, Head of R&D and CMO
- Posner Brian S, Director
- Friedl-Naderer Johanna, Chief Commercial Officer
- Cox John, CEO & President
- Lucera Erick, Chief Financial Officer
- Kersten Dirk, Director